Jade S. Schiffman

Teprotumumab for the Treatment of Active Thyroid Eye Disease

Raymond S. Douglas, George J. Kahaly, Amy Patel et al. · New England Journal of Medicine · 2020 · 700 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +11

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

David S. Hong, Razelle Kurzrock, Aung Naing et al. · Investigational New Drugs · 2013 · 211 citations

Medicine, Oncology, Pharmacology +15

Spectrum of Pediatric Neuromyelitis Optica

Timothy Lotze, Jennifer L. Northrop, George J. Hutton et al. · PEDIATRICS · 2008 · 173 citations

Medicine, Neurology, Pediatrics +17

Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment

Raymond S. Douglas, George J. Kahaly, Shoaib Ugradar et al. · Ophthalmology · 2021 · 158 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +13

Photopic ERGs in Patients with Optic Neuropathies: Comparison with Primate ERGs after Pharmacologic Blockade of Inner Retina

Nalini Rangaswamy, Laura J. Frishman, E. Ulysses Dorotheo et al. · Investigative Ophthalmology & Visual Science · 2004 · 137 citations

Medicine, Neurology, Ophthalmology +17